Barclays
IMNM icon

Barclays’s Immunome IMNM Stock Holding History

Barclays’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Buy
26,351
+2,497
+10% +$53.4K ﹤0.01% 3149
2026
Q1 		$522K Sell
23,854
-222,211
-90% -$4.95M ﹤0.01% 3167
2025
Q4 		$5.29M Buy
246,065
+37,552
+18% +$659K ﹤0.01% 2176
2025
Q3 		$2.44M Sell
208,513
-21,360
-9% -$212K ﹤0.01% 2741
2025
Q2 		$2.14M Buy
229,873
+103,294
+82% +$847K ﹤0.01% 2790
2025
Q1 		$852K Buy
126,579
+22,265
+21% +$214K ﹤0.01% 3201
2024
Q4 		$1.11M Sell
104,314
-1,572
-1% -$19K ﹤0.01% 3315
2024
Q3 		$1.55M Buy
105,886
+59,016
+126% +$839K ﹤0.01% 3059
2024
Q2 		$567K Buy
46,870
+17,876
+62% +$280K ﹤0.01% 2971
2024
Q1 		$716K Sell
28,994
-53,461
-65% -$1.08M ﹤0.01% 3355
2023
Q4 		$882K Buy
+82,455
New +$686K ﹤0.01% 3528

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Barclays's IMNM Position: Q2 2026 in Review

Barclays increased its Immunome (IMNM) stake by 10% in Q2 2026, buying an estimated $53.4K and bringing the position to 26,351 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #3149.

Barclays first reported a position in IMNM in Q4 2023 and has held it in 11 quarters since. The position peaked at $5.29M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Barclays held 26,351 shares of Immunome worth $558K as of Q2 2026.
  • Barclays bought 2,497 Immunome shares in Q2 2026, an estimated $53.4K.
  • Immunome made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3149 holding.
  • Barclays first reported a position in Immunome in Q4 2023 and has held it in 11 quarters since.
  • Barclays's Immunome position peaked at $5.29M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.